ATE219776T1 - Matrizenmetalloproteinase-inhibitor-peptide - Google Patents

Matrizenmetalloproteinase-inhibitor-peptide

Info

Publication number: ATE219776T1
Authority: AT; Austria
Prior art keywords: inhibitor; protein; metalloproteinase; timp; solid phase
Prior art date: 1989-03-21

Application number

AT90905905T

Other languages

English (en)

Inventor

William G Stetler-Stevenson

Lance A Liotta

Henry Krutzsch

Original Assignee

Us Secretary United States Dep

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-21

Filing date

1990-03-21

Publication date

2002-07-15

1990-03-21 Application filed by Us Secretary United States Dep filed Critical Us Secretary United States Dep

2002-07-15 Application granted granted Critical

2002-07-15 Publication of ATE219776T1 publication Critical patent/ATE219776T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
101710170181 Metalloproteinase inhibitor Proteins 0.000 title 1
HPNSNYBUADCFDR-UHFFFAOYSA-N chromafenozide Chemical compound CC1=CC(C)=CC(C(=O)N(NC(=O)C=2C(=C3CCCOC3=CC=2)C)C(C)(C)C)=C1 HPNSNYBUADCFDR-UHFFFAOYSA-N 0.000 title 1
229940126170 metalloproteinase inhibitor Drugs 0.000 title 1
239000003475 metalloproteinase inhibitor Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 5
108090000623 proteins and genes Proteins 0.000 abstract 5
239000003112 inhibitor Substances 0.000 abstract 3
238000011282 treatment Methods 0.000 abstract 3
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 abstract 2
102000005741 Metalloproteases Human genes 0.000 abstract 2
108010006035 Metalloproteases Proteins 0.000 abstract 2
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
201000001441 melanoma Diseases 0.000 abstract 2
239000007790 solid phase Substances 0.000 abstract 2
ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 abstract 1
102000029816 Collagenase Human genes 0.000 abstract 1
108060005980 Collagenase Proteins 0.000 abstract 1
108020004414 DNA Proteins 0.000 abstract 1
102000053602 DNA Human genes 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 abstract 1
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
238000000636 Northern blotting Methods 0.000 abstract 1
108020004511 Recombinant DNA Proteins 0.000 abstract 1
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 abstract 1
108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 abstract 1
102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
238000001042 affinity chromatography Methods 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
229960002424 collagenase Drugs 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940088598 enzyme Drugs 0.000 abstract 1
239000002532 enzyme inhibitor Substances 0.000 abstract 1
229940125532 enzyme inhibitor Drugs 0.000 abstract 1
210000002744 extracellular matrix Anatomy 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
230000001394 metastastic effect Effects 0.000 abstract 1
206010061289 metastatic neoplasm Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
230000009826 neoplastic cell growth Effects 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 1
239000002644 phorbol ester Substances 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
238000012163 sequencing technique Methods 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT90905905T 1989-03-21 1990-03-21 Matrizenmetalloproteinase-inhibitor-peptide ATE219776T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US32633489A	1989-03-21	1989-03-21
US38043189A	1989-07-17	1989-07-17
US39545389A	1989-08-18	1989-08-18
US49479690A	1990-03-13	1990-03-13
PCT/US1990/001526 WO1990011287A1 (en)	1989-03-21	1990-03-21	Matrix metalloproteinase inhibitor peptides

Publications (1)

Publication Number	Publication Date
ATE219776T1 true ATE219776T1 (de)	2002-07-15

Family

ID=27502330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90905905T ATE219776T1 (de)	1989-03-21	1990-03-21	Matrizenmetalloproteinase-inhibitor-peptide

Country Status (7)

Country	Link
US (1)	US5595885A (de)
EP (1)	EP0464147B1 (de)
JP (1)	JP3156082B2 (de)
AT (1)	ATE219776T1 (de)
AU (1)	AU634533B2 (de)
DE (1)	DE69033982T2 (de)
WO (1)	WO1990011287A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714465A (en)	1989-05-19	1998-02-03	Amgen Inc.	Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
JP2877509B2 (ja) *	1989-05-19	1999-03-31	アムジエン・インコーポレーテツド	メタロプロテイナーゼ阻害剤
JP3017591B2 (ja)	1992-01-17	2000-03-13	富士薬品工業株式会社	抗ヒトｔｉｍｐ−２モノクローナル抗体の製法およびその利用
WO1993018794A1 (en) *	1992-03-26	1993-09-30	Gensia, Inc.	In vivo peptide therapy
DE4304309A1 (de) *	1993-02-12	1994-08-18	Hoechst Ag	Biegsame Cycloolefincopolymer-Folie
DE4304310A1 (de) *	1993-02-12	1994-08-18	Hoechst Ag	Teilkristalline Cycloolefin-Copolymer-Folie
JP3809656B2 (ja) *	1993-04-26	2006-08-16	オリエンタル酵母工業株式会社	ゼラチナーゼａ活性阻害剤
AU7827794A (en) *	1993-08-12	1995-03-14	Regents Of The University Of California, The	Human timp-3
US6562596B1 (en) *	1993-10-06	2003-05-13	Amgen Inc.	Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
GB9601042D0 (en) *	1996-01-17	1996-03-20	Smithkline Beecham Plc	Medical use
GB9414157D0 (en) *	1994-07-13	1994-08-31	Smithkline Beecham Plc	Medical use
CN1129666C (zh) *	1994-12-13	2003-12-03	人体基因组科学有限公司	金属蛋白酶－4的人组织抑制剂
US6544761B2 (en)	1994-12-13	2003-04-08	Human Genome Sciences, Inc.	Human tissue inhibitor of metalloproteinase-4
AU708829B2 (en) *	1994-12-13	1999-08-12	Human Genome Sciences, Inc.	Human tissue inhibitor of metalloproteinase-4
JP2864219B2 (ja) *	1995-02-20	1999-03-03	富士薬品工業株式会社	遊離の活性型マトリックスメタロプロテアーゼ類の分別定量法
WO1996033733A1 (en) *	1995-04-25	1996-10-31	Fuji Yakuhin Kogyo Kabushiki Kaisha	Novel remedy for skin deficiencies
GB9607287D0 (en) *	1996-04-09	1996-06-12	British Biotech Pharm	Diagnosis method
US5786146A (en) *	1996-06-03	1998-07-28	The Johns Hopkins University School Of Medicine	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en)	1996-06-03	2000-01-25	The Johns Hopkins University School Of Medicine	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6022948A (en)	1996-09-17	2000-02-08	Washington University	Method of cell surface activation and inhibition
NZ335864A (en)	1996-11-06	2001-09-28	Univ California	Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
CA2367213A1 (en)	1999-03-18	2000-09-21	Children's Medical Center Corporation	Novel antiangiogenic peptides
DE19957065B4 (de) *	1999-11-26	2005-01-05	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Screening-Verfahren für Arzneistoffe
JP4074043B2 (ja) *	2000-03-27	2008-04-09	株式会社資生堂	皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
CA2404696C (en) *	2000-04-05	2010-06-15	Ipf Pharmaceuticals Gmbh	Medicament containing tissue inhibitor of metalloproteinases-2 (timp-2) as an osteoanabolically active substance
GB0015761D0 (en) *	2000-06-27	2000-08-16	Univ Bristol	Polypeptide
US6673623B1 (en)	2000-09-12	2004-01-06	Novocure, Inc.	Methods and compositions that control lipid production
US20020073441A1 (en)	2000-12-13	2002-06-13	Ross Brian D.	Compositions and methods for detecting proteolytic activity
US7247704B2 (en) *	2000-12-18	2007-07-24	Arriva Pharmaceuticals, Inc.	Multifunctional protease inhibitors and their use in treatment of disease
US6600057B2 (en)	2000-12-29	2003-07-29	Kimberly-Clark Worldwide, Inc.	Matrix metalloproteinase inhibitors
US7041787B2 (en)	2000-12-29	2006-05-09	Kimberly-Clark Worldwide, Inc.	Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
DE10102784A1 (de) *	2001-01-22	2002-08-01	Henkel Kgaa	Kosmetische oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20040072750A1 (en) *	2001-05-03	2004-04-15	David Phillips	Compounds and methods for the modulation of CD154
US20050019743A1 (en) *	2001-05-03	2005-01-27	Center For Blood Research, Inc.	Compounds and methods for improving platelet recovery and function
US6861504B2 (en) *	2001-05-03	2005-03-01	Cbr, Inc.	Compounds and methods for the modulation of CD154
US20030119073A1 (en) *	2001-12-21	2003-06-26	Stephen Quirk	Sensors and methods of detection for proteinase enzymes
KR100441384B1 (ko) *	2002-01-08	2004-07-21	주식회사 안지오랩	인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
CN1732023A (zh) *	2002-12-27	2006-02-08	血管技术国际股份公司	组合物和使用collajolie的方法
US20040225077A1 (en)	2002-12-30	2004-11-11	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
WO2006013114A1 (en) *	2004-08-06	2006-02-09	Develogen Aktiengesellschaft	Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2007048102A2 (en) *	2005-10-18	2007-04-26	The Government Of The United States, As Represented By The Secretary Of Health And Human Services	Angio-inhibitory peptides derived from human timp-2
US8802627B2 (en)	2008-10-09	2014-08-12	Oriental Yeast Co., Ltd.	Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2
US10487148B2 (en)	2010-01-28	2019-11-26	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for treating aging-associated impairments
US10626399B2 (en)	2010-01-28	2020-04-21	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en)	2010-01-28	2016-07-21	The Board Of Trustees Of The Leland Stanford Junior University	Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en)	2011-04-08	2015-10-20	The Board Of Trustees Of The Leland Stanford Junior University	Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
KR101363455B1 (ko) *	2011-09-09	2014-02-21	(주)케어젠	매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
US10905779B2 (en)	2013-12-09	2021-02-02	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening human blood products comprising plasma using immunocompromised rodent models
JP6667438B2 (ja)	2013-12-09	2020-03-18	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	老化に関連する状態を処置する方法及び組成物
ES2902467T3 (es)	2015-06-15	2022-03-28	Univ Leland Stanford Junior	TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento
EP3606554A4 (de)	2017-04-05	2020-12-09	Astute Medical, Inc.	Tests auf timp2 mit verbesserter leistung bei biologischen proben

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8500341D0 (en) *	1985-01-07	1985-02-13	Celltech Ltd	Production of protein
DE69011433T2 (de) *	1989-05-26	1995-04-06	Univ Washington	Gewebeinhibitor für Metalloproteasen (TIMP-2).

1990
- 1990-03-21 AT AT90905905T patent/ATE219776T1/de not_active IP Right Cessation
- 1990-03-21 DE DE69033982T patent/DE69033982T2/de not_active Expired - Lifetime
- 1990-03-21 EP EP90905905A patent/EP0464147B1/de not_active Expired - Lifetime
- 1990-03-21 AU AU53591/90A patent/AU634533B2/en not_active Expired
- 1990-03-21 WO PCT/US1990/001526 patent/WO1990011287A1/en not_active Ceased
- 1990-03-21 JP JP50552390A patent/JP3156082B2/ja not_active Expired - Lifetime
1993
- 1993-03-29 US US08/039,525 patent/US5595885A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP3156082B2 (ja)	2001-04-16
WO1990011287A1 (en)	1990-10-04
EP0464147A1 (de)	1992-01-08
EP0464147B1 (de)	2002-06-26
US5595885A (en)	1997-01-21
DE69033982T2 (de)	2002-10-24
AU5359190A (en)	1990-10-22
DE69033982D1 (de)	2002-08-01
AU634533B2 (en)	1993-02-25
JPH04504418A (ja)	1992-08-06
EP0464147A4 (en)	1992-08-19

Legal Events

Date	Code	Title	Description
2002-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69033982D1 (de)	2002-08-01	Matrizenmetalloproteinase-inhibitor-peptide
Ni et al.	1997	Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins
Stubbs et al.	1997	The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin: implications for the structure of human mast cell tryptase and its inhibition
Little et al.	1987	Location of two cysteines in brain β1-tubulin that can be cross-linked after removal of exchangeable GTP
RU94028712A (ru)	1997-03-10	Полипептид, протеаза, днк, вектор, способ ингибирования активности, способ лечения
NZ269871A (en)	1998-03-25	Haemopoietic maturation factor and coding sequences
Dahlbäck et al.	1984	Ultrastructure of C4b-binding protein fragments formed by limited proteolysis using chymotrypsin.
RU95113418A (ru)	1997-07-20	Полипептиды, способы получения, днк, вектор, клетка, применение полипептида, фармацевтические композиции
US5698671A (en)	1997-12-16	Metalloproteinase peptides
US7182945B2 (en)	2007-02-27	Anti-inflammatory peptides derived from C-reactive protein
Gechtman et al.	1993	Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin: Use in mapping the PAI-1 binding site
Owen et al.	1988	Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity
HUP9900979A2 (hu)	1999-07-28	Endoteliális sejtek proliferációját gátló inhibitor és eljárás alkalmazására
Ireland et al.	1991	Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin
JP3439490B2 (ja)	2003-08-25	蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
US4810780A (en)	1989-03-07	Protein having phospholipase A2 inhibitory activity
US6737507B2 (en)	2004-05-18	Antiangiogenic peptides and compositions thereof
CA2315976C (en)	2011-06-28	Serine protease inhibitors
Stetler-Stevenson et al.	1997	Matrix metalloproteinase inhibitor peptides
Galat et al.	1994	Cyclophilin‐B is an abundant protein whose conformation is similar to cyclophilin‐A
JP4742365B2 (ja)	2011-08-10	チロシナーゼ阻害剤、美白剤および美白外用剤
CA2046649A1 (en)	1990-09-22	Matrix metalloproteinase inhibitor peptides
KR101369502B1 (ko)	2014-03-03	ｄｈＦａｓ-1 도메인과 ＭＭＰ기질을 포함하는 융합 펩타이드 및 이를 유효성분으로 포함하는 염증성 질환의 예방 및 치료용 약학적 조성물
Joubert	1984	Proteinase inhibitors from lonchocarpus capassa (appleleaf) seed
Fioretti et al.	1989	Interaction between leukocytic elastase and Kunitz-type inhibitors from bovine spleen